NVCR vs. GMED, STVN, INSP, IART, SWAV, MMSI, HAE, ICUI, IRTC, and NARI
Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Globus Medical (GMED), Stevanato Group (STVN), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Shockwave Medical (SWAV), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), iRhythm Technologies (IRTC), and Inari Medical (NARI). These companies are all part of the "surgical & medical instruments" industry.
NovoCure vs.
Globus Medical (NYSE:GMED) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
Globus Medical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
In the previous week, NovoCure had 1 more articles in the media than Globus Medical. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.75 beat NovoCure's score of 0.18 indicating that Globus Medical is being referred to more favorably in the media.
Globus Medical currently has a consensus price target of $70.91, suggesting a potential upside of 33.44%. NovoCure has a consensus price target of $87.33, suggesting a potential upside of 52.76%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Globus Medical.
Globus Medical received 74 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 68.86% of users gave Globus Medical an outperform vote while only 65.29% of users gave NovoCure an outperform vote.
Globus Medical has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Globus Medical has a net margin of 18.59% compared to NovoCure's net margin of -17.20%. Globus Medical's return on equity of 11.93% beat NovoCure's return on equity.
74.2% of Globus Medical shares are owned by institutional investors. Comparatively, 78.4% of NovoCure shares are owned by institutional investors. 24.4% of Globus Medical shares are owned by company insiders. Comparatively, 6.2% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Globus Medical beats NovoCure on 13 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NovoCure Competitors List